Cargando…
Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
SIMPLE SUMMARY: Several studies suggested an enhanced efficacy of conventional treatments (CT, i.e., chemotherapy +/− targeted therapy) administered after immune checkpoint inhibitors (ICI) in certain tumor types, but no data are available concerning metastatic colorectal cancer (mCRC) patients harb...
Autores principales: | Bui, Quang Loc, Mas, Léo, Hollebecque, Antoine, Tougeron, David, de la Fouchardière, Christelle, Pudlarz, Thomas, Alouani, Emily, Guimbaud, Rosine, Taieb, Julien, André, Thierry, Colle, Raphaël, Cohen, Romain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774125/ https://www.ncbi.nlm.nih.gov/pubmed/35053568 http://dx.doi.org/10.3390/cancers14020406 |
Ejemplares similares
-
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022) -
Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023) -
BRAF
(V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023) -
Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
por: Mulet-Margalef, Núria, et al.
Publicado: (2023) -
Prognostic value of Lynch syndrome, BRAF(V600E)
, and
RAS
mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
por: Zwart, Koen, et al.
Publicado: (2023)